Good Doctor Cloud Healthcare Makes Second Bid for Hong Kong Listing: 3.8 Billion Yuan in Revenue Struggles to Mask 1.4% Net Profit Margin, 600 Million Yuan Performance-Based Agreement Countdown Tickin

ZC Asia has learnt that with less than nine months remaining until the listing deadline stipulated in the performance-based agreement, Sichuan Good Doctor Cloud Healthcare Technology Group Co., Ltd. (hereinafter referred to as “Good Doctor Cloud Healthcare”) resubmitted its prospectus to the Hong Kong Stock Exchange on 10 April. This marks the company’s second attempt following the lapse of its initial filing in September 2025.

Dubbed the “Pinduoduo of the healthcare sector”, the company has grown its revenue from 3.065 billion yuan to 3.823 billion yuan over three years, with services covering over 99% of China’s county-level administrative regions and 670,000 primary healthcare facilities. However, behind these impressive figures lie multiple challenges concerning profitability, cash flow and family governance.

Annual revenue of 3.8 billion, net profit of less than 54 million

Good Doctor Cloud Healthcare’s business model is straightforward: it produces affordable medicines through private-label manufacturing, bypassing intermediaries to supply clinics and pharmacies directly in counties, towns and villages. The prospectus states that this model “can help clients reduce unit procurement costs by up to 50% under optimal conditions”.

In terms of scale, this strategy has certainly paid off. Between 2023 and 2025, the company’s revenue rose from 3.065 billion yuan to 3.823 billion yuan, representing a compound annual growth rate of 11.7% over the three-year period. Based on 2024 revenue, the company ranks second in China’s direct-to-market pharmaceutical supply sector for primary healthcare and first in the laboratory diagnostics solutions market.

However, the performance on the profit front is far less impressive than the revenue figures. Net profit stood at 62.479 million yuan in 2023, plummeting to 37.806 million yuan in 2024—a year-on-year decline of nearly 40%. Although it rebounded to 54.052 million yuan in 2025, it has yet to return to the level seen two years prior. Based on 2025 revenue, the net profit margin was a mere 1.4%—meaning that for every 100 yuan of revenue, the company retained less than 1.5 yuan.

The decline in gross profit margin is equally concerning. During the reporting period, the company’s overall gross profit margin fell from 29.9% to 22.9%, a drop of 7 percentage points over two years. The business segment specialising in specialised disease diagnosis and treatment solutions saw the sharpest decline in gross profit margin, plummeting from 56.9% to 31.9%.

Cash reserves below 60 million yuan, performance-based liabilities exceeding 600 million yuan

More pressing than the slim profit margins is the cash flow crisis.

As of the end of 2025, the company’s cash and cash equivalents stood at just 58.517 million yuan. Meanwhile, net assets plummeted from 216 million yuan in 2024 to 16.993 million yuan, a contraction of over 90%. Net current assets turned negative, falling from 270 million yuan in 2023 to -135 million yuan, leaving the company in a state of net current liabilities.

Weighing heavily on the company is a “mountain of performance-based liabilities”. The prospectus reveals that as of the end of February 2026, the company’s total debt stood at 679 million yuan, with liabilities arising from the redemption of equity shares accounting for over 90% of this figure, amounting to 633 million yuan.

These liabilities stem from performance-based clauses in the company’s Series A, Series B and subsequent financing rounds. According to disclosures, should the company fail to complete a listing on the Main Board of the Hong Kong Stock Exchange or be acquired by 31 December 2026, investors are entitled to demand redemption at 1 to 1.2 times their principal investment, plus annualised interest of 6% to 8%. This implies that Good Doctor Cloud Healthcare has less than nine months remaining.

Following the expiry of the initial filing, the sponsor for this IPO has been changed from CITIC Securities to Haitong International as the sole sponsor. Analysts point out that the Hong Kong Stock Exchange imposes strict requirements regarding “going concern”, and the company’s current financial position may raise regulatory concerns; even if it passes the listing hearing, the offering price will come under pressure.

Private-label business: a “pharmaceutical distributor” without a pharmaceutical manufacturer

It is no coincidence that Good Doctor Cloud Healthcare is dubbed the “Pinduoduo of healthcare”. Its core revenue stream—direct supply and distribution of medicines—is projected to contribute 3.028 billion yuan in revenue in 2025, accounting for 79.2% of the total. Of this, revenue from proprietary-brand medicines (i.e. private-label products) reached 2.027 billion yuan, with a gross margin of 28.3%; whereas the gross margin for third-party brand distribution stood at just 3.9%.

The company owns 16 proprietary brands, including ‘Shuhan Bencao’, ‘Fuxin’ and ‘Gufang Xuanhu’. The top three best-selling products are all traditional Chinese patent medicines from the ‘Shuhan Bencao’ series, manufactured under contract by companies such as Wuhan Juneng Jinshi Pharmaceutical, Guangxi Shiwanshan Pharmaceutical and Jilin Songliao Pharmaceutical.

It is worth noting that Good Doctor Cloud Healthcare holds no registration or production licences for any chronic disease medications. In other words, this company, with annual revenue of 3.8 billion yuan, is essentially a “pharmaceutical distributor without a pharmaceutical factory” – relying entirely on contract manufacturers for critical aspects such as product quality, production processes and raw material procurement.

The prospectus contains mostly general descriptions regarding quality control, such as “carefully selected sources” and “ “strict supplier vetting” and other general principles, without disclosing specific records of quality incidents or regulatory penalties. However, as national oversight of pharmaceutical quality continues to tighten—notably with the March 2026 joint issuance by three government departments of the “Guiding Opinions on Medical Insurance Support for the Development of Primary Healthcare Services”, which imposes higher requirements on supply chain traceability and quality assurance—the policy risks associated with the contract manufacturing model are on the rise.

Family holds 66% stake; second generation has taken over

In terms of corporate governance, Good Doctor Cloud Healthcare exhibits distinct characteristics of a family-run enterprise.

Founder Geng Funeng, together with his younger brother Geng Fuchang, daughter Geng Jie, son Geng Yuefei, and son-in-law Xue Yuan, collectively control approximately 65.99% of the company’s voting rights through a concerted action agreement.

Geng Jie, aged 39, has taken over as Chair of the Board, overseeing the company’s overall strategy and management. She holds a Bachelor’s degree in Mathematics from the University of Waterloo in Canada and has gained extensive experience within the Good Doctor Pharmaceutical Group. Her husband, Xue Yuan, serves as Executive Director and Chief Technology Officer, whilst her elder brother, Geng Yuefei, serves as a Non-Executive Director.

This model of “founders establishing the business, children taking over, and in-laws providing support” is coming under scrutiny from institutional investors in the Hong Kong stock market. Some observers believe that a highly concentrated family-controlled structure may depress the company’s listing valuation and undermine investor confidence.

With only about eight months remaining until the deadline for the performance-based agreement at the end of 2026, the question of whether Good Doctor Cloud Healthcare can complete its listing within this window, and how it will present its long-term “low-margin, high-volume” narrative to the market, is gradually being revealed as the countdown continues.

Disclaimer: The content herein is for reference only and does not constitute any form of investment advice. Should any information contained herein prove inaccurate, incomplete, or potentially misleading, please refer to the company's official announcements. Market risks exist; investment requires caution.